Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Change in Accured Expenses (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Change in Accured Expenses for 11 consecutive years, with -$328315.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 23.88% to -$328315.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.7 million through Dec 2025, down 549.13% year-over-year, with the annual reading at -$1.7 million for FY2025, 549.13% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$328315.0 at Marker Therapeutics, up from -$1.9 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $2.9 million in Q2 2022, with the low at -$4.0 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $141085.2, with a median of $98515.0 recorded in 2023.
  • Peak annual rise in Change in Accured Expenses hit 960.07% in 2024, while the deepest fall reached 977.65% in 2024.
  • Over 5 years, Change in Accured Expenses stood at $1.4 million in 2021, then tumbled by 173.65% to -$1.0 million in 2022, then soared by 244.51% to $1.5 million in 2023, then plummeted by 128.96% to -$431297.0 in 2024, then grew by 23.88% to -$328315.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$328315.0, -$1.9 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.